Navigation Links
AstraZeneca Receives Complete Response Letter From US FDA For BRILINTA™ (Ticagrelor Tablets)
Date:12/16/2010

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

In the CRL, the FDA requested additional analyses of the PLATO data. The agency did not request that additional studies, including clinical studies, be conducted as a prerequisite for approval of the ticagrelor NDA.

AstraZeneca is evaluating the contents of the CRL and will respond to the agency's request for additional analyses of the PLATO data as soon as possible. The company remains confident in the NDA submission for ticagrelor and in its ability to respond to the agency's questions.

"Our highest priority is to provide the requested PLATO analyses to the FDA and progress to completion of the BRILINTA NDA review," said Martin Mackay, President, Research & Development, AstraZeneca.

NOTES TO EDITORS

About BRILINTA™ (ticagrelor tablets)

BRILINTA is an oral antiplatelet treatment for acute coronary syndromes (ACS). BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILINTA is the first reversibly-binding oral ADP receptor antagonist.

BRILINTA is currently under regulatory review in eighteen territories around the world and was granted marketing authorization under the trade name BRILIQUE™ by the European Commission (EC) on December 6, 2010.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About the PLATO study

PLATO was a large (18,624 patients in 43 countries) head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed to establish whether ticagrelor could achieve clinically meaningful cardiovascular and safety end points in ACS patients, above and beyond those afforded by clopidogrel. The NDA submission for ticagrelor is based on the results of a comprehensive clinical trial program, including data from the PLATO study.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or the AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... 2017 IBM (NYSE: IBM ) has been ... Solid-State Arrays (SSA) for the fourth year in a row. ... Gartner, "Vendors in the Leaders quadrant have the highest scores ... vendor in the Leaders quadrant has the market share, credibility, ... of new technologies. These vendors demonstrate a clear understanding of ...
(Date:7/21/2017)... you know that PhRMA member companies invested $65.5 billion in research ... medicines, generics and the supply chain account for 14 percent of ... this (7 percent)? Or that the United States ... in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for ...
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
Breaking Medicine Technology:
(Date:7/25/2017)... Texas (PRWEB) , ... July 25, 2017 , ... ... fastest growing ATM provider in the United States, today announced its partnership with ... financial institutions. , The foundation of the solution lies within Hyosung’s superior ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric patients ... The Emergency Room opened early March, making it the first SignatureCare Emergency ... are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re glad ...
(Date:7/24/2017)... JACKSONVILLE, Florida (PRWEB) , ... ... ... Klaproth, Division Marketing Director,      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins ... guests joined together to celebrate the structural topping out of the new ...
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center is looking to ... fall semester to a deserving student. Get your applications in now as the ... to Mariana Castillo who is a nursing student at Prairie View A&M University with ...
Breaking Medicine News(10 mins):